Back to Search

Vepugratinib for Advanced Bladder Cancer

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Recruiting Phase 3 Interventional Study
Carcinoma, Transitional Cell Urinary Bladder Neoplasms Neoplasm Metastasis
More trials: Cancer clinical trials· Cancer trials in Arizona
Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
450 (estimated)
Sponsor
Eli Lilly and Company · Industry
Who this trial is looking for

This trial is looking for people with advanced or spreading bladder cancer. Participants will take the medicine vepugratinib along with other treatments and will be followed for up to about 6 years.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have advanced bladder cancer that cannot be surgically removed.
  • I have a specific genetic change in my tumor or blood.
  • I have measurable cancer that can be assessed.
  • I have an ECOG performance status of 0 to 2.
  • I have adequate lab test results.

You may not be able to join if

  • I have received other treatments for my cancer before.
  • I have serious unresolved side effects from previous treatments.
  • I have ongoing nerve problems that are moderate or severe.
  • I have untreated or uncontrolled brain cancer.
  • I have eye problems confirmed by an eye exam.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab. Study participation could last up to approximately 6 years.

Trial Locations

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Have histologically confirmed, unresectable locally advanced or metastatic urothelial cancer (mUC). Individuals with mixed histology other than small cell or neuroendocrine carcinoma are eligible if a urothelial component is present. * Have a qualifying fibroblast growth facto…
Contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

1-317-615-4559

LillyTrials@Lilly.com

CONTACT

Physicians interested in becoming principal investigators please contact

clinical_inquiry_hub@lilly.com

CONTACT

NCT ID: NCT07218380 Source: ClinicalTrials.gov